ACADIA Pharmaceuticals Announces Appointment Of Terrence Moore As Executive Vice President And Chief Commercial Officer
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, announced the
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced the appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer, effective today. Mr. Moore reports to ACADIA’s Chief Executive Officer, Uli Hacksell, Ph.D., and will be responsible for leading ACADIA’s commercial activities. “Terry is an exceptional individual who brings a wealth of commercial experience to ACADIA from a variety of senior roles at several leading pharmaceutical companies. He has made key contributions to the building of multi-billion dollar brands in the CNS field, including Prozac ®, Zyprexa ®, Risperdal ®, and Effexor XR ®,” said Dr. Hacksell. “Terry’s marketing expertise and demonstrated ability to execute will help position ACADIA for success in the planned launch of pimavanserin in Parkinson’s disease psychosis and for effective life cycle management in order to maximize pimavanserin’s commercial potential.” Mr. Moore has more than 25 years of experience as a senior member of sales and marketing teams at several pharmaceutical companies. Most recently, Mr. Moore was a principal of Cook-Moore Consulting and, before founding the firm, served as Vice President at Transcept Pharmaceuticals, where he was responsible for commercial strategy, business development and commercial alliance activities. Previously, Mr. Moore served as Vice President, U.S. Head of Neuroscience Marketing at Organon BioSciences and was responsible for the creation and building of its Neuroscience Business Unit. He also served as Vice President, U.S. Marketing, Effexor XR ®, as well as Vice President, Global Strategy Depression Portfolio at Wyeth Pharmaceuticals. Earlier, Mr. Moore held senior management positions at Johnson & Johnson, where he helped to launch Risperdal ® for additional indications in the U.S., and at Eli Lilly, where he held various sales and marketing roles over 11 years, including Zyprexa ® Brand Manager. Mr. Moore holds a B.S. degree in Pharmacy from the University of Florida, a B.A. degree in Chemistry from the University of South Florida and has completed executive development programs at the Kellogg School of Management and Wharton School of Business.